Longitude Capital

company

About

Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.

  • 11 - 50

Details

Industries
Angel Investment,Biotechnology,Finance,Financial Services,Venture Capital
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
Venture Capital

Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.

Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment.

Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.

Investments

Number of Investments
Number of Lead Investments
7
5
Longitude Capital has made 7 investments. Their most recent investment was on Dec 14, 2022, when Alpha9 Theranostics raised $75M.
Date Company Name
Round Money Raised Industry Lead Investor
Series B $75M Biotechnology
Feb 22, 2022 Somatus
Series E $325M Health Care
Series A $11M Biotechnology Yes
Jul 29, 2020 Eargo
Series E $81.57M Audio Yes
Jun 23, 2020 Somatus
Series C $64M Health Care Yes